United States - English - NLM (National Library of Medicine)

apotex corp - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - brimonidine tartrate and timolol maleate ophthalmic solution 0.2%/0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop; the iop-lowering of brimonidine tartrate and timolol maleate ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [ see warnings and precautions   ( 5.1 , 5.3 ) ] . brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patie

United States - English - NLM (National Library of Medicine)

pacific pharma, inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - brimonidine tartrate and timolol maleate ophthalmic solution 0.2%/0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop; the iop-lowering of brimonidine tartrate and timolol maleate ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [ see warnings and precautions   ( 5.1 , 5.3 ) ] . brimonidine tartrate and timolol maleate ophthalmic solution is contraindicated in patie

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 2.5 mg in 1 ml - timoptic ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timoptic is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. timoptic ® (tim-op´tik) (timolol maleate ophthalmic solution) 0.25% and 0.5% read this instructions for use that comes with timoptic before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timoptic: • use timoptic exactly as your doctor tells you to use it. your doctor will tell you how much timoptic to use and when to use it. • if

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 2.5 mg in 1 ml - timoptic-xe sterile ophthalmic gel forming solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timoptic-xe is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings, obstructive pulmonary disease ]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings, cardiac failure ]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. timoptic-xe® (tim-op´tik-xe) (timolol maleate ophthalmic gel forming solution) 0.25% and 0.5% read this instructions for use that comes with timoptic-xe before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timoptic-xe: how should i use timoptic-xe? step 1

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - timolol maleate, quantity: 3.4 mg/ml (equivalent: timolol, qty 2.5 mg/ml) - eye drops, solution - excipient ingredients: sodium hydroxide; dibasic sodium phosphate dodecahydrate; benzalkonium chloride; water for injections; monobasic sodium phosphate dihydrate - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: water for injections; monobasic sodium phosphate dihydrate; sodium hydroxide; dibasic sodium phosphate dodecahydrate; benzalkonium chloride - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - timolol maleate, quantity: 3.4 mg/ml (equivalent: timolol, qty 2.5 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; sodium hydroxide; water for injections - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; water for injections; dibasic sodium phosphate dodecahydrate; sodium hydroxide; monobasic sodium phosphate dihydrate - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - timolol maleate -

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol gfs 0.25% and 0.5% are indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol gfs is contraindicated in patients with: • bronchial asthma • history of bronchial asthma • severe chronic obstructive pulmonary disease • sinus bradycardia • second or third degree atrioventricular block • overt cardiac failure • cardiogenic shock • hypersensitivity to any component of this product. teratogenic effects pregnancy category c: teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. doses of 1,000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity. there are no adequate and well-controlled studies in pregnant women. timolol gfs should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. timolol maleate has been detected in human milk following oral and ophthalmic drug administration. because of the potential for serious adverse reactions in nursing infants from timolol gfs, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. safety and iop-lowering effect of timolol gfs 0.25% and 0.5% has been demonstrated in pediatric patients in a 3-month, multicenter, double-masked, active-controlled trial. no overall differences in safety or effectiveness have been observed between elderly and younger patients.